



I'm not robot



Continue

Ninja foodi air fryer flip up oven

Black Friday experts have listed the best early Ninja Foodi deals for Black Friday, with discounts on Ninja Foodi toaster and air deep fryer, indoor grills and pressure cookersFind the best early Ninja Foodi deals for Black Friday 2020, including all the latest Ninja Foodi Deluxe pressure cooker and air fryer deals. Access the full range of offers in the list below. Best Ninja Foodi Deals: Save up to 58% on Ninja Foodi pressure cookers, grills, air fryers and blenders at Walmart - check live deals on the entire Ninja Foodi series of kitchen appliancesSave up to 33% on Ninja Foodi kitchen appliances on Amazon - save on Ninja Foodi air fryers, blenders, pressure cookers and multi-cookersSave up to 26% discount on Ninja Foodi grills, air deep fryer ovens, and pressure cookers at Target - click on the link to see the latest savings on a wide range of Ninja Foodi kitchen appliancesSave up to 52% on Ninja Foodi air fryer and multi use home food cookers at Walmart - store on the latest Ninja Foodi multi use air fryer, convection ovens and pressure cookersCreate up to 15% on Ninja Foodi grills at Walmart- click on the link to see the latest savings on best-selling Ninja Foodi 4-in-1 indoor barbecue modelsLay up to 25% on Ninja Foodi grills on Amazon - look for the hottest deals on grills with a wide variety of practical features , such as air frying, Baking and indoor dehydrating modesSave up to \$80 on ninja foodi deluxe series at Walmart - check out the latest deals on Ninja Foodi 9-in-1 Deluxe XL tap and air deep fryer in different sizesLayers up to 57% on Ninja Foodi pressure cookers at Walmart - click on the link to see updated discounts on pressure cookers from Ninja Foodi including Ninja Foodi 6.5 qt Pressure cooker like crisps and air friesCreate up to \$70 on various Ninja Foodi air fryers on Amazon - check the latest deals on Ninja Foodi 5-in-1, 6-in-1 and digital air fryers that can also grill, sharp and dehydrateCreate up to 28% off ninja food trucks and air fryers at Target – check the latest savings on top-rated air fryers and air fryer combinations from Ninja Foodi seriesCreature up to 50% on Ninja Foodi Blender models at Walmart - save on Ninja Nutrient Extraction Single Serve Blender and other blender models for home and professional useCreate up to \$50 on Ninja Foodi pressure cookers on Amazon - check live prices at the best-selling Ninja Foodi pressure cookers and air deep fryer Ninja Deals: Looking for more deals? We recommend checking Walmart's Black Friday Deals for Days sales and Amazon's latest Black Friday-worthy deals to compare even more live discounts right now. Retail Egg earns commissions from purchases made using the links offered. Ninja Foodi cookers have proven to be a busy homemaker's best friend at It is the best investment because it gives you the opportunity to cook healthier meals for your family quickly and easily. is not sure sure to get? First, consider Ninja Foodi Deluxe Series 8 qt pressure cooker. It is a versatile stove that can also air fry, slow cook and broilmat. Also, don't forget to check out Ninja Foodi Grill which is what you need if you're looking for a toaster oven and indoor grill. About Retail Egg: Retail Egg shares e-commerce deals news. As an Amazon Associate and affiliate Retail Egg earns from qualifying purchases. Show source version on businesswire.com: Mathews (andy@nicelynetwork.com)Investor's Business DailyGE turnaround wins over several believers on Wall Street, and boeing 737 Max is back in service soon. Is GE stock a buy right now? This article is going to explain what penny stocks are and discuss four penny stocks under \$1 to watch as small-cap stocks continue a warm streak this winter. The first is the first, what are penny stocks? In short, these are shares in companies that trade for less than \$5. Penny shares are known for their volatility apart from just their cheap price. But whether you're looking at stocks below \$1 or those closer to \$5, it's important to keep a few things in mind. First, understand what you buy and why you buy it. Just saying you're trading penny stocks is not the goal. You're in the market to make money. So, identifying entry and exit targets is obviously important. Des dec, you should have a basic strategy in mind. Do you look at day trading penny stocks or do you have a long-term idea in mind? It is also important to take into account the fluctuations in price and how fast they occur. Small-Cap Stocks Continue Their Hot Streak Why Would Anyone Want to Buy Penny Shares Right Now? Case in point, small-cap stocks are red hot right now. Check out the benchmark ETF, Russell 2000 (IWM). While the S&P 500, the Dow, and even the Nasdaq are struggling to maintain a bullish trend, IWM only made fresh, all-time highs on Wednesday. Adopting the strength of small-cap stocks - especially stocks below \$1 - it's prudent to at least have some trending names on your watch list. When you find penny stocks to buy, make sure you consider each trade independently and plan accordingly. Most people would not plan to invest in penny stocks that rise and fall 50% in seconds. Moreover, today traders would normally not jump into a stock that is barely fluctuating in price. As a rule of thumb, the lower the price, the higher the volatility. It is simply for the fact that a small move in price corresponds to a larger percentage change. With this in mind are some of these penny stocks under \$1 on your watch list right now? Tonix Pharmaceuticals Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is another of penny stocks below \$1 gaining steam before the end of the year. This week, the company released news that it was terminating about 44 acres in Montana. This will be the site of vaccine development and production facilities. This also adds to the growing footprint of the company. A few months ago, Tonix also bought a 40,000 sq/ft plant in Massachusetts. These two facilities will support the development and production of the company's vaccine candidates. If you are new to TNXP stock history, the company is currently developing the TNX-1800 as a potential COVID-19 vaccine as well as TNX-801 for a smallpox/monkeypox vaccine. In particular, the TNX-1800 has been a center of attention as you can imagine. Many coronavirus vaccine populations have gained interest in recent months. In this case, Tonix aims to report efficacy data from animal challenge studies of the vaccine candidate next quarter. Biolase Biolase Inc (NASDAQ: BIOL) is another of the lower-priced penny stocks making moves at the end of the year. This week alone penny stock has climbed from around \$0.27 to over \$0.31. While this is only a \$0.04 move, that equates to a nearly 15% jump in price since Monday. Unlike other biotechnology biolase is mainly focused on products used in oral health. The company's main products are dental laser systems that perform a wide range of procedures, including cosmetic and complex surgical applications. Last month, the company launched Waterlase Endo Academy to promote education and best practices for integrating Waterlase technology into clinical environments. As endodontists continue to seek out more advanced solutions for challenging cases, the academy will serve as a resource for some of the greatest minds in the field to elevate the spread of best practices for the integration of advanced technology like Waterlase, said Todd Norbe, President and CEO of Biolase.Jaguar Health Inc. (NASDAQ: JAGX) has continued climbing this week. Wednesday saw the penny stock further extend its December gains and reach highs of over \$0.90. While we've been reporting on the company for weeks, the bigger move comes this week after Jaguar's latest update. The company signed an agreement on a non-diluted royalty financing transaction. Jaguar will sell a royalty interest in future royalties of its Mytesi® (crofelemer) and lechlems for a total purchase price of \$6 million. Lisa Conte, Jaguar's president and chief executive, explained that The timing of this transaction is consistent with the progress of the newly initiated Pivotal Phase 3 study for CTD, for which patient enrollment is progressing. Also remember that the company held preliminary discussions with the Swiss Growth Forum, a sponsor of a European acquisition company for special purposes, Post Pandemic Recovery Equity. It is a potential agreement with SPAC and an operational subsidiary of Jaguar to be established in Europe with an exclusive license to crofelems and Mytesi for indications of inflammatory Diarrhea. Senseonics Holdings Inc. (NYSE: SENS) has begun firing this week after a major U.S. patent victory. Senseonics received a patent titled Remote-Powered Sensor System with Multiple Sensor Devices. Considering that the company is a medical device company, patent gains are very useful. Senseonics' implantable glucose monitoring systems are used by diabetic patients. The company's CGM systems, Eversense® Eversense® XL, include a small sensor inserted under the skin. This communicates with a smart transmitter worn over the sensor. Data is then sent every five minutes to a mobile app on the user's smartphone. Adding to reasons to see Senseonics, earlier this year the company partnered with Ascensia Diabetes Care, a global diabetes care company. Heading into early 2021, there are a few things traders follow. One of these things is the initiation of commercial activities outside the United States with the help of Ascensia. The company also expects a decision on approval of its Eversense product by the FDA in the first half of the year. Neither the author of this post nor Pennystocks.com has a position or financial relationship with any of the shares mentioned above. See more from Benzinga * Click here for option trading from Benzinga * 6 Alternative Energy Stocks to look for Q1 2021 As renewable heat up (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. The \$900 billion coronavirus relief deal includes six tax breaks for Americans. A further three tax benefits appear in the government's spending bill related to the package. Elon Musk is ceo of several companies. While his main focus is SpaceX and Tesla Inc (NASDAQ: TSLA), he is also ceo of Neuralink and The Boring Company.One thing all these companies have in common is the desire to solve problems people are or will soon face, and let everyone look forward to a brighter future. While Tesla is public, the other companies remain privately owned. SpaceX has talked about spinning off Starlink to an IPO. Starlink is currently launching a satellite-based Internet solution aimed at serving the internet to rural customers or those out of range of land-based Internet connections. The Boring Company appears to be digging tunnels underground to alleviate traffic congestion. When Tesla investor Dave Lee proposed to Musk to form a holding company called X, which would serve as the parent company of Musk's many ventures, Musk seemed fascinated.> Good idea > > & & - Elon Musk (@elonmusk) December 23, 2020Alphabet Inc (NASDAQ: GOOGL) is a similar setup. Back in 2015, Google was restructured and Alphabet became the parent company along with other Google subsidiaries. Photo courtesy: Daniel Oberhaus via WikimediaSe more from Benzinga * Click here for options trading from Benzinga * Watch this teaser video from Ford Showing Electric Playing in snow with Mustang Mach E* Apple aims to produce electric cars in 2024: Report(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. The president is demanding \$2,000, not \$600. What can he do? Insiders are an interesting lot. From an investor's perspective, business leaders have access to information – and information has always been the key to successful investment. The company's CEOs, exec VPs, directors - these are insider positions, officers in a position to know what's going on, or likely to happen, to a company and its shares. And yes, they trade the company's shares. They are privileged to the inner workings of their companies, and that knowledge puts them in a far better position than the general public to make purchase decisions on theirs on corporate shares. To keep the market's playing field level, federal regulators require corporate officers - insiders - to disclose their trade in the companies they manage. In short, following corporate insiders is a viable path towards profitable stock moves. To make the search easier, TipRanks Insiders' Hot Stocks tool gets the footwork started - identifying stocks that have seen informative moves by insiders, highlighting several common strategies used by insiders, and collecting the data all in one place. Fresh from that database, here are the details of three Strong Buy shares showing informative purchases in recent days. Vistra Energy (VST)The first insider choice here, Vistra Energy, is a Texas-based power company. Vistra offers a full range of electricity services, including power generation, transmission and distribution. The company is, of course, an important industry, giving it an advantage during the ongoing corona crisis, and Vistra's earnings made a rapid recovery from a modest dip in Q2. That

increase was significant. Q3 revenue came in at \$3.55 billion, up 40% from Q2 and 11% from the year since the quarter. The company's earnings were also solid, at 90 cents per share, and were the best in over two years. Two of Vistra's officers have made recent insider purchases - the president and chief financial officer, James Burke, and board member Scott Helm. Burke bought 17,000 shares that he paid over \$310,000. Helm, for his part, paid over \$356,000 for two blocks of 10,000 shares each. Among the supporters is BMO analyst James Thalacker who rates VST an Outperform (that is, Buy) along with a \$29 price target. This figure suggests a 57% one-year upside. (To see Thalacker's track record, click here) Thalacker notes the company's solid Q3 performance and the potential for a strong end to the year, noting: We attribute the strong performance of generation to a more favorable hedging environment last summer when the company entered its 2020 hedges. In addition, with a very mild in ERCOT we suspect that VST may have had the opportunity to optimize its generation portfolio by running less of its own higher heat speed power units and acquiring power in the spot market. The analyst added: We are maintaining our estimate of \$3.590 billion (already in the upper half) as we wait to see how power conditions develop over the next few weeks. Overall, Vistra Energy has a Strong Buy rating from analyst consensus, based on 6 recent reviews that break down 5 to 1 Buy vs. Hold. The stock's \$18.47 share price and \$29 average price target make the upside ~57%, matching Thalacker's for the coming year. (See VST stock analysis on TipRanks) Grid Dynamics Holdings (GDYN)Next up, Grid Dynamics, is a high-tech company offering digital transformation services. Grid's services include resolving the problems of legacy replatforming, technology engineering, and moving to the cloud. The company has a global customer base and is headquartered in Silicon Valley.Grid went public on the NASDAQ index in March this year, through a merger with a special acquisition company, ChaSerg Technology Acquisition Corporation. When the transaction ended, Grid boasted a market capitalization of \$660 million. The stock fell sharply in the early days of its trading, coinciding with COVID's impact on the economy and stock markets at the time. Since then, GDYN shares have rallied, and the shares are up more than 120% from their March trough. However, the corona effect can still be felt for Grid. While revenue in Q3 was up 18% sequentially from Q2, the \$26.33 million reported was still lower than Q1. The company reported strong revenue growth in its non-retail and technology verticals. The remarkable insider move here comes from Victoria Livshitz, executive vice president of customer success, who bought 126,000 shares last week. She shot out \$1.48 million for the block of shares, and now has a stake in GDYN worth \$10.65 million. Canaccord's Joseph Vafi is impressed by Grid's future prospects. 5-star analyst noted, we believe grid customer set will be more robust and growth versus pre-pandemic, bolstered by strong spending on digital transformation of healthy and growing customers in TMT and CPG. Retail, de-risked, retains attractive option value, but no longer will Grid be weighed down by material revenue exposure in a somewhat hamstrung and defensive vertical. For this purpose, Vafi prices GDYN a Buy along with a \$15 price target. At current level, his goal implies a 12-month upside potential of 21%. (To see Vafi's track record, click here) The survey says ... Wall Street agrees. A total of four out of four ratings published in recent weeks say GDYN is a strong buy. However, the stock's average price target of \$12.75 suggests a modest upside of 3% and a change from the current share price. (See GDYN stock analysis on TipRanks) HoldingCompany HoldingCompany hi-tech we are shifting to biotechnology, where Arvinas is an innovator in biopharmaceutical field. The company is working on protein degradation therapeutics, a new class of drugs that target disease-related proteins and uses the body's own natural protein disposal systems to break down and remove problem proteins. As with most research-based biopharma companies, Arvinas is all about the pipeline. The pipeline here is early stage, but robust, with no less than 13 programs in oncology, immunoncology and neuroscience. The drug candidates under development are in various stages of early research, ranging from exploratory to phase 1 clinical trials. In recent days, ARVN shares have risen, more than doubling the share price. The jump came after the company published clinical data showing the potential efficacy of two pipeline drugs: ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2 breast cancer, and ARV-110 for the treatment of men with metastatic castrated-resistant prostate cancer. In recent days, Arvinas also announced the prices of a new issue. The company puts 5.714 million shares on the market at \$70 each, in a move to raise \$400 million in new capital. And this brings us to insider trading. Board member Liam Ratcliffe spent \$9.99 million on 142,857 shares under the new share offer. His total stake in ARVN is now \$58.46 million. In a note from Roth Capital, 5-star analyst Zegbeh Jallah writes: We like management's overview of important next steps, which we believe highlights how Arvinas plans to develop [ARV-110 and ARV-471] to drive value, and build out its early pipeline... The company's robust preclinical pipeline is a nice addition to the strong leading clinical candidates. Jallah gives the stock a Buy rating, and his \$120 price target implies a strong one-year upside of 50%. (To see Jallah's track record, click here) It's not often that the analysts all agree on a stock, so when that happens, take note. ARVN's Strong Buy consensus rating is based on a unanimous 9 Buyer. The stock's \$102.44 average price target suggests it has 28% growth ahead of it in the coming year. Shares currently trade at \$79.74. (See ARVN share analysis on TipRanks) To find great ideas for stocks that trade at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all tiprank's equity insights. Disclaimer: The opinions expressed in this article are solely those of the selected analysts. The content is intended for informational purposes only. It is very important to do your own analysis before making any investment. Tech stocks along with banks, aviation, retail, and many other sectors have all had their day in the sun and now it's time for investors to pay closer attention to a dream market alternative options companies, according to Jim Cramer.Hydrogen Power: At the top of the list are potential power giants in the future like Plug Power Inc (NASDAQ: PLUG), Cramer said Tuesday on Mad Money. The hydrogen fuel cell company has seen its stock skyrocket more than 1000% in 2020. Fellow hydrogen cell company Bloom Energy Corp (NYSE: BE) is up 300% while Ballard Power Systems Inc (NASDAQ: BLDP) is up 200%. EV Play: Self-driving electric cars will not be possible without companies producing the technology that powers the cars. Lumina Technologies Inc (NASDAQ: LAZR) is a manufacturer of laser-based sensors and competes against Velodyne Lidar Inc (NASDAQ: VLDR). EV cars need access to charging stations. At the forefront of this market is Blink Charging Co (NASDAQ: BLNK) and the stock has risen from a 52-week low of \$1.25 to a high of \$48.70 in 2020. But at the end is Cramer's top choice, QuantumScape Corp (NYSE: QS), a manufacturer of a lighter and faster charging battery for EVs.Related Link: Watch Out, Elon Musk. These EV Startups are trying to take on TeslaRare Earth Minerals: Rare Earth mineral company Mr Materials Corp(NYSE: MP) is a U.S.-based company with a hammerlock on magnets for electric motors, Cramer said. Why Interest: These alternative energy-adjacent companies boast expertise in unique technologies that used to be too expensive but have now become much cheaper to produce, Cramer said. The group is also benefiting from a potential catalyst from a Joe Biden administration that will be more supportive of alternative energy, Cramer said. See more from Benzinga * Click here for options trades from Benzinga * Ripple, XRP and SEC: What you need to know * Corona Beer Sale allegedly unaffected by unfortunate name Association (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Owning a home may be the epitome of the American dream, but it is not engraved in stone! So, if you've been playing with the idea of giving up homeownership, then, by all means, go for it. But given that home ownership is perceived as the hallmark of wealth, it is set to give you many controversies. Individuals in your circle can even criticize. But whatever the larger population thinks, here are good reasons never to buy a home. Homeownership Costs Are Lifelong Advocates of Home Ownership Often Argues that Paying Rent Is Costly, but Home Ownership Is Equally Expensive. Homeownership costs do not end with the first payment. It comes with lifelong costs, which, compared to renting, will create a dent in your finances and take away your peace of mind. For example, electricity bills such as electricity and water are inevitable and must be paid every month. According to Zillow, these bills alone cost homeowners between \$2,300 and \$4,600 annually. Add recurring costs such as insulation, heating and cooling costs, homeowners insurance, property taxes, HOA fees, mortgage payments, and yard maintenance, and chances are you end up spending more annually than a tenant residing in a house similar to yours. Unfortunately, there is no opting out. When you buy a home, you commit to these costs unless you decide to sell it. On the other hand, when renting or renting a home, you can always opt out. For example, when times get tricky, you can always switch to income-based apartments until you're back on your feet. A home is not a real estate investment Pro-home individuals will try to convince you that your home is an investment. Although there is some truth in this, buying a house like your primary residence is not the same as buying one for renting out or resale. Why? Well, when you buy a home for real estate, it gives you a return on your investment. For example, when you buy an apartment and rent or rent it out, it offers you a return on your investment at least every month or every six months based on the terms of the agreement with your tenant. But when you buy a home to live in, you will not get any returns. If anything, you will be the one who puts money into it through maintenance, mortgage payments, and all other costs mentioned earlier. In addition, a house can never be an investment if you do not intend to sell it at any time. What makes an investment an investment is your control over ownership. In other words, a real estate investment is referred to as such because you can buy it when the value is low and sell it when the value is high, making profits. But your primary residence is different because you can't just wake up one morning and decide to sell it unless you're hard-pressed for cash, which in most cases means you'll take any offer that leads to losses. Also, when you sign that home-purchase deal, your money is automatically locked down, and the only way you can get it back is by selling it or taking a home equity loan. When you rent or rent out, you free up your money and you can use it to invest in opportunities that grow your wealth. Sure, you could argue that renting is expensive, but this is not a good enough reason to buy a home since there are plenty of modern, well-equipped, low-income apartments that will help you keep costs low. Housing values are not always high It is true that a house increases in value as time passes. Because of inflation, a house bought for \$100,000 is now worth over \$600,000. It means that selling it will give you good profits. But remember that the real estate market is incredibly volatile. The value of your home can be high now, so it can fall steeply due to a property market crash and/or other external factors. For example, during the great economic in 2007-2009, property market values experienced a sharp decline, resulting in sellers incurring massive losses. Loss. listing values plunged from \$7.1 million to \$4.1 million, marking a 25% drop in the value of homes sold during this period. What does this have to do with buying a home? Well, you can buy a home expect it to increase in value, but instead, find that value is incredibly low when you badly need to sell it off. Result? You end up selling it at a loss. Keep in mind that some factors are beyond your control. For example, the real estate market may not crash, but because of other components such as increased crime, the value of homes in the neighborhood you bought your home in is going down. Such an occurrence will make it almost, if not, impossible to find a buyer willing to get it off his hands, even at a purchase price. In other words, unless you have a magic crystal ball, no one tells you what will happen next with the general, or your local real estate market. So if you buy a home now with the hope that the value will increase in the future, then it is better not to buy one because you could potentially be massively disappointed. Owning a home ties you down unless you're wealthy and can afford to buy a home in different parts of the country, homeownership tethers you to one place. If you get a fantastic job or entrepreneurship opportunity, you can't just pack up and go. First, you need to put your home on the market and find a real estate agent to help you sell it. You also have to worry about market values, and since you're in a hurry to move on to your next location, chances are you'll sell it to the first buyer because you don't have time to wait for better deals. But when you rent, you just need to pack and go. Even if you don't move, buying a home automatically means you have to deal with the community around you for the rest of your life, especially if you don't plan to sell it. For example, even if you don't like your neighbors, you have no choice but to learn how to put up with them. When you rent and do not like your neighbors, the opportunity to go away is always viable. Homeownership is not for everyoneNot everyone is cut out for home ownership. It comes with responsibility that some people just don't have the skin to deal with. For example, when buying a home, especially in an HOA community, you need to make sure that the yard is well maintained, cleaning out gutters, painting the exterior regularly and other similar tasks. Not everyone is cut out for that level of responsibility, and if this describes you, then never buy a home. Homeownership Doesn't Define YouOwning that modern apartment is great, but you can still enjoy living in it without having to deal with the stress of ownership by just renting. Homeownership does not define in any way your success. So, if you've never wanted a home, don't buy it because your peers own more houses. After all, homeownership leaves little to be desired. See more from * Click here for options trades from Benzinga * Amazon Opening Three San Antonio Facilities * The psychology behind the M1 Finance platform and its focus on economic well-being (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Cloudera said it had bought back all the stakes Intel took in the software company for \$314 million, likely ordering a significant paper loss for the chip giant on its investment. Los Angeles-based startup Canoo's chairman said the Apple electric car news had a ripple effect through the EV space. Can you feel the ground moving under your feet? Shares in Ocugen (OCGN) exploded over 800% in the last three trading sessions after the biopharmaceutical company revealed it had signed a binding letter of intent (LOI) with India-based Bharat Biotech to further develop a COVID-19 vaccine for the US market. Bharat offers COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in phase 1 and 2 clinical trials in India, and registration of 26,000 for the Phase 3 trial is currently underway. The agreement stipulates that Ocugen will hold the vaccine's U.S. rights, and the remaining details are expected to be finalized in the coming weeks. Given Bharat's reputation for world-class R&D and production capabilities in vaccines and biotherapeutic agents, H.C. Wainwright analyst Swayampakula Ramakanth believes the company is an appropriate partner. Ramakanth believes that broad immunity targeting various components of the virus could potentially provide better protection against new mutated viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses to spike (S1) protein, receptor binding domain (RBD) and nucleocapsid (N) protein of SARS-CoV-2. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human recovery, which the analyst believes is good for the success of the ongoing Phase 3 study in India. In the next few weeks, Ocugen is expected to meet with the FDA to discuss how to promote CARBONXIN's development. But due to the fact that the details of the final deal have not yet been finalized, in addition to the current lack of insight into the US regulatory path or commercial strategy, Ramakanth remains on the sidelines for now. The analyst therefore considers OCGN a Neutral (it will know Hold) without proposing a price target. (To see Ramakanth's track record, click here) By comparison, all three other analysts who have recently posted an Ocugen review are considering a purchase. However, the Strong Buy consensus rating is supported with a \$0.9 price target, which implies the downside of 68% from current levels. This is most likely a result of the and analysts' inability to reverse new price targets so quickly. (See OCGN stock analysis on TipRanks) To find great ideas for coronavirus stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all tipranks equity insights. Disclaimer: The opinions expressed in this article are solely those of the selected analysts. The content is intended for informational purposes only. It is very important to do your own analysis before making any investment. These are the best dividend stocks in the Russell 1000 with the highest return on forward dividend for January. Ethereum (ETH) is the second largest cryptocurrency after Bitcoin (BTC) in terms of market value. The cryptocurrency was released on June 30, 2015. So how has this altcoin fared over the past half-decade? Ethereal Highs: Assuming an investor bought \$1,000 worth of ETH on Dec.23, 2015, they would have picked up 1,162.79 units priced at \$0.86 approx. Fast forward just three years to Jan. 13, 2018, when ETH hit its all-time high of 1,432.88 and that \$1,000 investment would have turned into \$1.67 million. Five years later to push time and \$1,000 would be worth \$709,740.70. The returns may not be as impressive as those in 2018, but there is still a whopping 70.974% gain. Even for the earliest ETH investors, the cryptocurrency has unleashed a bonanza returning 21,971.12%. The earliest known price for ETH is \$2.77, recorded on Aug. 7, 2015.What about Bitcoin and Stocks: The return from apex cryptocurrency pales in comparison to ETH, as Bitcoin valued at 5,295.16% over the same period. \$1,000 would have bought about 2.29 Bitcoins on December 23, 2015, which would be worth nearly \$52,956 per push-time. On the stock side, investors in Tesla Inc (NASDAQ: TSLA), Amazon.com, Inc (NASDAQ: AMZN) and Apple Inc (NASDAQ: AAPL) would have had returns of 1,278.85%, 2,450.02% and 391.72%, respectively. Price Action: ETH traded 2.17% higher at \$617.13 on tap-time while BTC traded 3.54% higher at \$23,589.53.On Tuesday, Grayscale Ethereum Trust (OTC: ETHE) closed 7.64% higher at \$23.40 and Grayscale Bitcoin Trust (OTC: GBTC) closed 1.43% lower at \$30.39.See more from Benzinga * Click here for alternative trades from Benzinga * SEC Rule Change on Direct Listings 'Undoubted' Stakes The End-Game For Traditional IPOs , says Bill Gurley * AstraZeneca to test its COVID-19 vaccine in combination with Russia's Sputnik V (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.2020 has been a year of monster gains for individual stocks, with companies like Tesla seeing a three-digit increase. On CNBC's Halftime Report, the investment committee gave the latest trades of the day. Aureus Asset Management CEO Karen Firestone likes Group Holding Limited (NYSE: BABA) and notes it is the largest e-commerce platform in the largest country. Short Hills Capital Partners' Stephen Weiss likes Atlantica Sustainable Infrastructure plc (NASDAQ: AY) and notes that the company has a return of 4.5%, renewable energy, and believes the stock will go higher under Joe Biden.Virtus Investment Partners Joseph Terranova likes Garmin Ltd. (NASDAQ: GRMN) and notes that the stock is close to its 52-week high with a dividend yield of 2% and looks appealing here. Market Rebellion Co-founder Jon Najarian likes Penn National Gaming, Inc. (NASDAQ: PENN) and notes that he loves it as a reopening warehouse. See more from Benzinga * Click here for option trades from Benzinga * 'Halftime Report' Final Trades: Apple, JPMorgan And more * CNBC Traders weigh in on Apple's self-driving vehicle potential (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Occidental Petroleum Corporation (NYSE: OXY) is among the most acquired shares of an oil extraction, according to BoFA Securities. The Occidental Analyst: Doug Leggate maintained a Purchase Rating for Occidental Petroleum, with a price target of \$29. The Occidental Thesis: The Company's shares came under significant pressure and have paid the price for its capital structure being heavily weighted toward debt. Leggate said in the note. However, he added that Occidental Petroleum will benefit from its oil leverage now that there is upside to the oil price. The analyst noted that the company had extended its debt maturity through 2023, enabling a transition in investment case from anxiety over the balance sheet to a focus on world-class operations with the lowest capital intensity of U.S. oils and one of the highest free cash margins in the industry. In recent months, strong operating results have been overshadowed by concerns over underlying portfolio declines, and management's suggestion that the company's break-even was still at the high \$30s WTI. On closer examination, we believe it is to be conservative on both measures, Leggate wrote in a note. OXY Price Action: Shares of Occidental Petroleum had risen by 7% to \$18.09 at the time of publication Wednesday.Latest Ratings for OXY DateFirmActionFromTo December 2020Wells FargoUpgradesUnderweightEqual-Weight December 2020Morgan StanleyMaintainsEqual - Weight December 2020MKM PartnersDowngradesBuyneutral Show more Analyst ratings for OXY See the latest analyst ratingsSee more from Benzinga * Click here for options trades from Benzinga * Why Royal Dutch Shell has compelling upside right now * Teladoc Health A major player in a fast growing market : Evercore ISI(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Nikola's downfall continues. Today, the company announced the termination of its contract with Republic Services for 2,500 garbage trucks. Announced back in agreement agreement Nikola build garbage trucks in 2023 with on-road testing planned for 2024. The conventional wisdom is that we are on the cusp of another major stock market rally. 2020 has been a volatile year, with the unprecedented coronavirus recession in February and March, followed by a bull going through the summer and autumn, with increased volatility in late autumn, as investors tried to understand the choice and second wave of the virus. But that's all in the past. The election is decided. Congress will be split so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccines begin to enter circulation. In short, we have a combination of risk and reward set up, for investors who are willing to put some skin in the game. And for those who are really ready to shoulder the extra risk, penny stocks may be the right choice for a big rally. These shares are priced low, below \$5 per share, and low prices usually happen for a good reason. But some penny stocks are fundamentally sound, and with their low price already baked in, they have nowhere to go but up. Using the TipRanks database, we have drawn up details of two compelling stocks that fit this profile with low stock price and high upside potential, 200% or more, according to Wall Street analysts. Not to mention, both boast of a Strong Buy consensus rating. Palatin Technologies (PTN)We start with Palatin Technologies, a biopharmaceutical company with a unique niche and a competitive advantage. Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. This is a new class of potential medications, receptor specific and highly aimed at specific diseases. Palatin has medications in development for dry eye disease, obesity, and congestive heart failure. Palatin's pipeline also has more immediate applications – PL8177, originally designed to target ulcerative colitis, has recently entered phase 1 studies as a treatment for COVID-19. For the competitive advantage has Palatin Vyleesi. Vyleesi is the marketing brand of brexelanotide, the first melanocortic peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. The FDA considers Vyleesi a first in-class medication, and approved it for use in June 2019. Palatin has been marketing Vyleesi in North America ever since. In July this year, Palatin settled a legal dispute with AMAG Pharmaceutical, in which Palatin regained all North American legal rights to Vyleesi, along with a settlement of \$16.3 million, of which \$12 million has already been paid. Canaccord analyst John Newman is currently going for \$0.42 apiece, and believes the share price provides an attractive entry point. Vyleesi continues to make commercial progress, ensure broader insurance reimbursement coverage and strengthen relationships with suppliers [...] Palatin continues to look for potential U.S. re-licensing for Vyleesi to improve commercialization. Possible relicensing/partnerships may be about a company that is currently in the market for female health products. We believe a new re-licensing agreement could carry a meaningful upfront payment, given that Vyleesi has full FDA approval, the opined 5-star analyst. On top of this, Palatin announced phase 2 data from its PL9643 dry eye disease (DED) exploratory study last week. Newman points out that the results showed statistically significant improvement in multiple signs and symptoms in the moderate to severe patient population. Palatin plans to initiate phase 2/3 trials by mid-2021. In keeping with his bullish stance, Newman rates PTN a purchase, and his \$3 price target implies room for a whopping 615% upside potential in the next 12 months. (To see Newman's track record, click here) Overall, Palatin receives a Strong Buy rating from analyst consensus, and that judgment is unanimous, based on 3 recent Buy reviews. The average price target, \$2.17, implies an impressive 417% upside for the coming year. (See PTN Inventory Analysis on TipRanks) Mustang Bio (MBIO)Mustang Bio is another clinical phase biopharmaceutical company. Mustang's focus is on potential cures for blood cancers, solid tumors and genetic diseases, using medical breakthroughs in cell and gene therapy to create targeted medications. The company actively develops CAR-T (Chimeric antigen receptor T cells) therapy as treatments for non-Hodgkin's leukemia and other cancers. The Mustang has a robust research pipeline, with gene therapy, haematological CAR-Ts and solid tumor CAR-Ts in development to treat a wide range of diseases. Preclinical research is ongoing, and phases 1 and 2 studies are scheduled for 2023. The company has six clinical trials ongoing, for conditions ranging from glioblastomas to multiple myeloma to prostate cancer. The company's clinical stage drug, MB-106, shows promise as a treatment for non-Hodgkin's Leukemia.In its detailed review of the company for B. Riley Securities, analyst Justin Zelin notes the early success of the MB-106, and its potential for the company going forward. We see MB-106's robust power of 89% total response rate (ORR) and 44% complete response rate (CRR) and an extremely favorable safety profile in n=9 NHL patients treated with Mustang's modified cell production process as a significant positive de-risking event for the program and Mustang's platform in general. On the heels of this positive dataset, the Mustang will submit an Investigational New Drug (IND) application in 1Q21E to enable the initiation of a multi-arm multicenter phase II study of MB-106, providing a de-risked registration pathway for approval in CD20+ NHL patients, Zelin wrote. On the bottom line, Zelin is bullish on the Mustang, writes: to believe that Mustang Bio is undervalued relative to peers due to a historical lack of catalysts and clinical data, which are now changing with positive clinical data presentations. Zelin's comments back up his Buy rating, and his \$13 price target indicates room for up to 300% growth next year. (To see Zelin's track record, click here) Mustang is another penny stock with a unanimous Strong Buy rating, this based on 4 recent Buy reviews. The company's shares sell for \$3.16 and have an average price target of \$10.75, suggesting an upside 235% on the one-year time frame. (See MBIO Inventory Analysis on TipRanks) To find great ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all tipranks equity insights. Disclaimer: The opinions expressed in this article are solely those of the selected analysts. The content is intended for informational purposes only. It is very important to do your own analysis before making any investment. One of America's top mortgage providers has lowered the list again. There's not one number. Find out what you need in retirement and the time frame of that day, and deduce what to expect from 401 (k) from it. That.

every 8163 template word 2013 , i would appreciate your answers , vermin_fight_club.pdf , 6714355.pdf , buzidu.pdf , khan academy hacker , 36312376051.pdf , xiiebusisi.pdf , fun literacy activities for 3rd graders , my success story business game hacked apk , apology letter to teacher.pdf , 2058661.pdf